Header Logo

Connection

John Mordes to Immunosuppressive Agents

This is a "connection" page, showing publications John Mordes has written about Immunosuppressive Agents.
Connection Strength

0.140
  1. Seung E, Mordes JP, Greiner DL, Rossini AA. Induction of tolerance for islet transplantation for type 1 diabetes. Curr Diab Rep. 2003 Aug; 3(4):329-35.
    View in: PubMed
    Score: 0.046
  2. Waegell W, Babineau M, Hart M, Dixon K, McRae B, Wallace C, Leach M, Ratnofsky S, Belanger A, Hirst G, Rossini A, Appel M, Mordes J, Greiner D, Banerjee S. A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection. Transplant Proc. 2002 Aug; 34(5):1411-7.
    View in: PubMed
    Score: 0.042
  3. Bortell R, Moss J, McKenna RC, Rigby MR, Niedzwiecki D, Stevens LA, Patton WA, Mordes JP, Greiner DL, Rossini AA. Nicotinamide adenine dinucleotide (NAD) and its metabolites inhibit T lymphocyte proliferation: role of cell surface NAD glycohydrolase and pyrophosphatase activities. J Immunol. 2001 Aug 15; 167(4):2049-59.
    View in: PubMed
    Score: 0.040
  4. Iwakoshi NN, Mordes JP, Markees TG, Phillips NE, Rossini AA, Greiner DL. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol. 2000 Jan 01; 164(1):512-21.
    View in: PubMed
    Score: 0.009
  5. Rossini AA, Mordes JP, Like AA. Immunology of insulin-dependent diabetes mellitus. Annu Rev Immunol. 1985; 3:289-320.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.